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Overview of Urinary Incontinence 
 
Abstract 
Urinary incontinence is a common problem that is often under-reported due to the 
embarrassing nature and social stigma attached. Urinary incontinence can have a 
considerable effect on an individual’s quality of life, but can be significantly improved with 
correct assessment, treatment and management.  Conservative treatment options 
including: pelvic floor exercises, bladder retraining and fluid modification are recommended 
before referral to secondary services. This article provides an overview of the main types of 
urinary incontinence, and summarises recent guidelines for the assessment, diagnosis and effective 
conservative treatment options for them and when a referral for specialist care is required.   
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Introduction 
Urinary incontinence is a common problem that affects between 3 and 6 million people in the UK    
(Irwin et al, 2005 and Buckley and Lapitan, 2009). Urinary incontinence is more common in women 
than men, with prevalence increasing with age (Price and Currie, 2010). The impact of urinary 
incontinence on quality of life is well recognised (Tang et al 2014, Minassian et al, 2015). Many 
people do not seek help due to the embarrassing nature and social stigma attached (Berman, 
Berman and Felder, 2003). Following publication of the Francis report (Department of Health (DoH), 
2010) and a national audit of continence care (Healthcare Quality Improvement Partnership (HQIP) 
& Royal College of Physicians (RCP) 2010, pg 6), it was recommended that healthcare professionals 
should pro-actively ask individuals about symptoms of bladder incontinence to identify those who 
have a problem. There has been evidence in the past of nurses resorting to containment of 
incontinence without proper assessment and treatment (Booth et al 2009 and Ostaszkiewicz., 
O'Connell, Millar, 2008). The National Institute for Health and Care Excellence (NICE) guidelines 
(2015a and 2015b) state that absorbent products and other aids should not be used as a treatment 
option, but can be used alongside treatment for urinary incontinence where all treatment options 
have been explored.  Healthcare professionals should be able to provide an initial assessment and 
provide conservative treatment and also understand when to refer to a specialist.  The NICE 
guidelines for Urinary Incontinence in women: management (NICE, 2015a) and Lower urinary tract 
symptoms in men: management (NICE, 2015b) recommend initial conservative treatments including 
lifestyle advice, pelvic floor exercises, bladder retraining and pharmacological options, before 
referral for secondary treatment such as surgery is considered. 
Urinary incontinence is defined by the International Continence Society (Staskin et al, 2009 
and Abrams et al, 2002) as “a storage symptom and defined as the complaint of any 
involuntary loss of urine, where the loss of urine is a social or hygienic problem”. 
The main types on incontinence are: 
 Stress urinary incontinence – the involuntary leakage of urine on effort or exertion  
(such as sneezing or coughing), which raises the intra-abdominal presssure to that 
higher than the pelvic floor and bladder sphincter pressures. Stress incontinence is 
more common in women and is associated with pregnancy, childbirth, constipation 
and obesity. Stress incontinence is characteristically associated with small leakages 
and the leakage is momentary and ceases once the episode of raised intra-
abdominal pressure stops. 
 Urge incontinence – involuntary leakage accompanied by, or imediately preceded by, 
a sudden powerful desire to void which cannot or is difficult to defer (urgency). Urge 
urinary incontinence is part of a larger symptom complex known as overactive 
bladder syndrome (OAB). 
OAB is defined as urinary urgency which occurs with or without incontinence. Where 
incontinence occurs with OAB it is classsed as “OAB wet” and where there is no 
incontinence this is known as “OAB dry”. OAB is associated with increased voiding 
frequency and nocturia. Frequency is defined by the ICS as voiding > 7 times in 24 
hours.  These symptoms are suggestive of detrusor overactivity but can result from 
urinary retention and other forms of urethrovescical dysfunction. 
 Mixed urinary incontinence – is where involuntary leakage is associated with urgency 
and stress incontinence  
 Overflow incontinence occurs as a complication of urinary retention. When a person 
cannot empty their bladder completely and it becomes over-distended this can 
result in continuous, or frequent loss of urine. Urinary retention can be the result of 
pelvic/abdominal surgery, enlarged prostate, constipation, pregnancy, prolapse, 
medication and neurological impairment. Patients with overflow incontinence often 
experience urinary uregncy and frequency, small voided volumes, urinary hesitancy, 
a poor or diminished urine flow rate and nocturia.  
 Nocturnal enuresis is the involuntary leakage of urine at night and can be associated 
with OAB, medication and sleep apnoea. 
 
 Reflex incontinence is urinary leakage due to neurological damage, disease or a 
congenital abnormailty that results in failure of the bladder to store urine, to empty, 
or a combination of both.  Reflex incontinence is associated with urgency, urge 
incontinence and frequency, incomplete bladder emptying, urinary tract infections 
and loss of full bladder contents, but can vary. 
 Functional incontinence, has no organic cause and is associated with cognitive or 
physical factors that impair the persons ability to reach or use the toilet effectively. 
Functional incontinence is associated with impaired mobility, dexterity, 
dementia/cognitive impairment, confusion, poor eyesight, poor 
environment/change in environment and hospitalisation or institutionalism. 
(Definitions taken from National Institute for Health and Clinical Excellence (NICE) , 2015a 
and 2015b, Abrams et al, 2002 and NICE, 2012) 
  
Prevalence  
The reported prevalence of urinary  incontinence varies between 5-69% in women 
(Hunskaar et al, 2005) and 11-34% in men (Markland, et al. 2010) and increases increasing 
with age (Buckley and Lapitan, 2009). In the UK approxiametley 24% of older people are 
affected by urinary incontinence, with rates for those in institutioanl care between 30-60%  
(Hunskaar et al, 2004). Prevalence varies due to differing definitions, the popluation studied 
and measurements used (NICE, 2015a and NICE, 2015b).  
Incontinence is probably significantly under-reported due to the embarrassing nature of the 
problem and the social stigma and taboo that remains, with many people waiting a 
significant length of time before seeking help (Strickland, 2014, NICE 2015a, Porrett, 2010 
and Wennberg et al, 2009). Help seeking behaviour is affected by a number of issues 
including an individuals experience of incontinence (how much it bothers them), a 
percepotion that incontinence is an inevitable and normal part of ageing, lack of services or 
a lack of awareness of available services and knowledge of available treatments (Strickland, 
2014 and Wennberg et al, 2009). 
The main risk factors for devloping urinary incontinence are: 
 Damage during childbirth 
 Neurological conditions which affect the brain or spoinal cord such as, Stroke, 
Multiple Sclerosis and Parkinsons disease 
 Obesity 
 Damage due to surgery nearby or on the bladder, this can damage the nerves or the 
connective tissues. 
 Urinary tract infection 
 Certain medications 
 Congentital such as cerebral palsy 
 Constipation 
 Fluid intake – drinking too much alcohol or caffeine or poor fluid intake (can cause 
strong concentrated urine which can irritate the bladder and cause urgency and 
frequency 
 Physical disabilities that reduce mobility and dexterity. 
(NICE 2015a and NICE, 2015b)  
 Normal bladder function 
The bladder has two main functions: to store and expel urine. Remaining continent requires 
a complex interaction between detrusor muscle activity (contractions) and urethral 
sphincter closure pressure controlled by the nervous system. The bladder is innervated by 
the parasympathetic, sympathetic and somatic nervous systems which are controlled by the 
higher cortical and subcortical centers (Ouslander, 2004). In bladder storage, the urethral 
closure pressure needs to exceed the pressure from detrusor (bladder muscle) contractions. 
Any increases  in intra-abdominal pressure are transmitted to the urethra and bladder 
equally, resulting in continence. Normal voiding is achieved when urethral pressure falls and 
bladder pressure rises  (Getliffe and Dolman, 2007). Problems with this mechanism and the 
muscles can lead to incontinence.   
Receptors and neurotransmitters  
Many medication therapies for urinary incontinence are based on targeting the 
neurotransmitters required for voiding and maintaining urethral closure pressure. 
Coordination of voiding involves four principle neurotransmitters: glutamate, serotonin, 
noradrenaline and acetylcholine. The primary neurotransmitter in the parasympathetic 
neurons and somatic nerves is acetylcholine, noradrenaline is used in sympathetic neurons 
(de Groat., Griffiths and Yoshimura, 2015, Abrams et al, 2010 and Fowler., Griffiths and de 
Groat, 2008).  
Assessment 
 
A holistic and patient centered assessment is required to establish the presence and nature 
of bladder dysfunction and any contributory factors. An initial assessment should include a 
comprehensive symptom history, a focused physical examination (where required and 
appropriate) and laboratory testing such as urinalysis and blood tests in order to establish a 
working diagnosis and to exclude underlying organ specific related or unrelated conditions 
that may require attention (Staskin et al. 2009, NICE, 2015a and NICE, 2015b). Lower urinary 
tract symptoms are defined from the individual’s perspective, although they cannot provide 
a definitive diagnosis, conservative treatment can be instigated based on the initial 
assessment (Staskin et al. 2009, NICE, 2015a and NICE, 2015b). 
Health care professionals must be alert for any 'red flags' that might indicate a serious 
underlying condition (see the NICE guidelines NG12, 2015c). Referral should be made where 
any “red flags” are present. Healthcare professionals should consider referral to a 
continence service or consultant specialist where initial treatment/management has been 
unsuccessful or further tests are required. Table 1 includes the main “red flags” for prostate, 
bladder and renal cancer. 
 
Table 1 “Red Flags”– referral for patients using a suspected cancer pathway referral (taken 
from NICE guidelines NG12, 2015c) 
 
  
Prostate Cancer Consider a prostate-specific antigen (PSA) 
test and digital rectal examination to assess 
for prostate cancer in men with: 
 any lower urinary tract symptoms, such 
as nocturia, urinary frequency, 
hesitancy, urgency or retention or 
 erectile dysfunction or 
 visible haematuria.  
 PSA levels are above the age-specific 
reference range 
Refer men if their prostate feels malignant 
on digital rectal examination.  
Bladder Cancer Refer people if they are aged 45 and over 
and have: 
o unexplained visible haematuria 
without urinary tract infection or 
o visible haematuria that persists or 
recurs after successful treatment 
of urinary tract infection, or 
 aged 60 and over and have unexplained 
non-visible haematuria and either 
dysuria or a raised white cell count on 
a blood test.  
Renal Cancer Refer people if they are aged 45 and over 
and have: 
 unexplained visible haematuria 
without urinary tract infection or 
 visible haematuria that persists or 
recurs after successful treatment of 
urinary tract infection 
 
 
  
 
 
A bladder diary is important to record the patient’s day to day bladder habits. A bladder 
diary records diurnal and nocturnal patterns of voiding, functional and maximum bladder 
capacity, fluid intake and any circumstances associated with leakage. Bladder diaries should 
be kept for a minimum of 3 days and cover the persons usual activities such as working and 
leisure days (NICE, 2015a). The fluid balance chart establishes patterns and type of fluid 
intake. The types of fluid taken is important especially those that may irritate the bladder 
such as caffeinated, carbonated or citrus drinks (Miller et al, 2016, Lohsiriwat., Hirunsai and 
Chaiyaprasithi, 2011 and Maserejian et al, 2013).  
 
 
A holistic assessment needs to include the person’s desire for treatment, as this can be 
affected by previous experiences, personal values, motivation, expectations, 
mental/cognitive status, environment and physical status. Healthcare professionals as well 
as the person and/or their family may have an expectation of incontinence which may vary 
according to the patient’s age, for example people often believe that urinary incontinence is 
an inevitable part of aging (Martin., Williams and O'Neil, 2009). The assessment should also 
build up a picture of the person (such as the person’s family network/relationships, social 
activities, hobbies and employment history).  Bladder dysfunction can have a negative 
impact on a person’s perception of themselves and their body image, using a validated 
incontinence-specific Quality of Life (QOL) score for example the International Consultation 
on Incontinence Questionnaire (ICIQ), Bristol Female Lower Urinary Tract Symptoms 
questionnaire (BFLUTS) and Stress and Urge Incontinence and Quality-of-Life Questionnaire 
(SUIQQ) (Staskin et al. 2009, NICE, 2015a and NICE, 2015b) can help determine how the 
bladder dysfunction is affecting them individually.  
 
 
 Co-morbidities 
 
Consider any significant past medical, surgical, obstetric or genitourinary history. Any 
condition that may affect functioning of the kidneys and urine production, the function of 
the pelvic floor and genitourinary tract. Some examples of conditions to specifically consider 
are: 
 
o Diabetes mellitus can increase urine production and decrease bladder 
sensation due to peripheral neuropathy resulting in urgency and frequency, 
which may lead to incontinence if mobility and dexterity are also impaired 
(Burakgazi et al, 2012). 
o Heart disease can cause fluid retention and impaired renal function and as 
drug treatment increases urine output, frequency is common (Tannenbaum,  
and Johnell, 2014).  
o Arthritis is associated with impaired mobility and dexterity and can lead to 
functional incontinence (Turner-Stokes and Frank, 1992).  
o Multiple births/large babies may damage pelvic floor and cause stress urinary 
incontinence (NICE, 2015a). 
o Neurological conditions, which affect the brain and spinal cord, such as 
Parkinson’s disease or multiple sclerosis (NICE, 2012) 
o Obesity increases the pressure placed on the pelvic floor and pelvic organs 
(Subak., Richter and Hunskaar, 2009). 
  
 
 Physical examination 
 
This should only be carried out by a trained competent professionals and according to local 
policy, and should include: 
 
o Bladder palpation to identify retention – this should also be assessed using a 
bladder scanner or in/out catheter) (NICE, 2015a and 2015b)  
o Abdominal examination for masses (NICE, 2015a and 2015b) 
o Vaginal examination to identify atrophic vaginitis, pelvic organ prolapse and 
the strength and condition of the pelvic floor. Female patients should also be 
asked about bladder leakage during intercourse is also an important 
symptom to ascertain as it can provide a clue to the underlying pathology 
(NICE, 2015a).  
o Male patients should be offered an examination of the external genitalia and 
a digital rectal examination and prostate specific antigen (PSA) if their 
symptoms are suggestive of bladder outlet obstruction secondary to prostate 
enlergement (NICE, 2015b).  
 
 Investigations 
 
o Urinalysis to eliminate UTI, check for hydration (specific gravity) and diabetes 
o Post void residual urine measurement (bladder scanner or in/out catheter) to 
identify any incomplete bladder emptying and urinary retention. It is also 
important to drain any residual urine with an in/out catheter and then re-
scan the bladder after allowing to re-fill to decide whether the residual is a 
one off, or recurring problem.   
 
 
 Medication 
 
A comprehensive medication history should include prescribed, over the counter and herbal 
medicines as well as recreational drugs and illegal/illicit drugs. Ketamine use has been 
associated with symptoms including severe pain, frequency, haematuria and dysuria (Tsai 
and Kuo, 2015). The use of some psychoactive substances, mainly stimulants such as MDMA 
and amphetamine are associated with urinary retention (Skeldon and Goldenberg, 2014 and 
Selius and Subedi, 2008).  
 
It is important to consider a patient’s drug history, particularly in new onset incontinence 
and in the elderly, where polypharmacy is common (Duerden., Avery and Payne, 2013). 
Healthcare professionals should review the use of any medication and/or its side-effects 
that increases urine production, sedates, impairs cognition, affects sensation and muscle 
tone. Drugs that are commonly associated with urinary incontinence include sedative-
hypnotics, diuretics, anticholinergics, antispasmodics, analgesics, antihistamines, anti-
psychotics, alpha-adrenergic agonists, alpha-antagonists, calcium channel blockers, ACE 
inhibitors, and antiparkinsonian medications (Porter and Kaplan, 2011 and Tsakiris., Oelke 
and Michel, 2008 and British Medical Association (BMA) and the Royal Pharmaceutical 
Society (RPS), 2016).  
Depending upon the drugs mode of action, the effect may be direct or indirect and can lead 
to any of the types of incontinence. Drugs including those with anticholinergic properties or 
side effects, antidepressants, COX-2 inhibitors, antihistamines and opioids can result in 
chronic urinary retention can lead to overflow incontinence (Selius and Subedi, 2008 and 
BMA and RPS, 2016).  
Treatment options 
The options for treatment depend on the type of symptoms and underlying pathology. The 
initial treatment for all patients should include: 
 Adjustment and modification of fluid intake; i.e. if it is too high or too low and caffeine 
restriction (Lohsiriwat, Hirunsai and Chaiyaprasithi, 2011 and Maserejian et al., 
2013).  
 Treatment of constipation 
 Advice to stop smoking 
 Advice about weight loss if their BMI is over 30 (Lucas et al 2015)  
 Bladder retraining including time delayed voiding. 
 Pelvic floor training  
 Pharmacological therapy.  
(NICE, 2015a and NICE 2015b) 
Before using pharmacological therapies, fluid modification, bladder retraining and pelvic 
floor retraining should be tried. Secondary options include botox® injection into the bladder 
lining and surgery. Conservative therapies have been proven to be effective strategies and 
in motivated patients can be more effective than medication (NICE, 2015a).  
Health professionals should be able to inform patients of all the options available to them 
for the treatment and management of their condition to ensure that patients have the 
opportunity to make informed decisions (NICE, 2015a and NICE, 2015b).  Treatment and 
care should respect the patient’s individual needs and preferences. Professionals should 
form a partnership with patients enabling them to make informed decisions and choices. 
This also aids in improving concordance and reducing medication waste (NICE, 2009).  
 
Treatment options for Stress incontinence 
Pelvic Floor exercises remain the first line treatment option for stress incontinence, with a 
programme that comprises at least 8 contractions performed 3 times per day (NICE, 2015a).  
Duloxetine remains the only drug currently licensed for the treatment of SUI (BMA and RPS, 
2016). Duloxetine is a serotonin and noradrenaline reuptake inhibitor that acts mainly in the 
spinal cord to increase pudendal nerve activity, which increases urethral sphincter closure 
pressure within the storage phase (NICE, 2015a). Duloxetine is associated with a high 
incidence of adverse effects which include nausea, dry mouth and constipation, as such it 
also has a high discontinuation rate (NICE, 2015a). NICE (2015a) recommend Duloxetine as a 
second line therapy for women only if surgery is declined or unsuitable. 
For older women intravaginal oestrogen therapy can provide some improvement in the 
symptoms of UI especially in post-menopausal women with vaginal atrophy (Panay et al,  
2013 and NICE, 2015a). Intravaginal oestrogen has an effect on the bladder and urethral 
epithelium and can help to relieve symptoms of urinary frequency, urgency and possibly 
reduce recurrent urinary tract infections (Panay et al,  2013).  
Treatment options for Urge incontinence 
Drugs with an antimuscarinic or anticholinergic action remain the mainstay for the 
treatment and management of overactive bladder (NICE, 2015a and NICE, 2015b). 
Anticholinergic medications inhibit the binding of acetycholine on the muscarinic receptors 
within the detrusor. This decreases bladder (detrusor) contractions without inhibiting 
normal voiding, thus the ability of the bladder to store urine is increased and the frequency 
and urgency symptoms are reduced. The action and metabolism of the different 
anticholinergic medications varies depending on the affinity to a particular muscarinic or 
nicotinic receptor. Anticholinergic medications are associated with common adverse side 
effects such as constipation, dry mouth, blurred vision and somnolence. More serious side 
effects include cardiac and cognitive events (Robinson and Cardozo, 2012). 
Older patients are more susceptable to central nervous system effects, which include 
cognitive disturbances such as sedation, inability ot concentrate, memory impairment and 
delirium. This high rate of adverse effects is associated with poor concordance, with a 
reported discontinuation rate between 43-83% (Sexton et al, 2011).  
As anticholinergic drugs undergo hepatic metabolism involving cytochrome P450 
isoenzymes (in particular CYP3A4 and CYP2D6) and renal excretion, care should be taken in 
patients with renal or hepatic impairment. There is also a risk of postural hypertension. 
Concommittant use of other medications with anticholinergic properties such as 
antihistamines, may increase the risk of side effects (Robinson and Cardozo, 2012). As a 
result of the increased adverse effect lower doses should always be considered in older 
patients. Tropsium chloride has no selectivity for muscarinic receptor subtypes. It is not 
metabolised by the cytochrome P450 system, and is expected to cross the blood-brain 
barrier only to a limited extent, which results in fewer negative cognitive side effects, which 
can make it a useful choice in older patients (Widemann, Fusgen and Hauri, 2001). 
There are a number of different anticholinergic drugs licensed for OAB treatment within the 
UK. NICE (2015a) recommends that: oxybutynin (immediate release, IR), tolterodine 
(immediate release, IR) or darifenacin modified release (MR) (once daily preparation) are 
the first choices for OAB or mixed UI.  
If the first treatment for OAB or mixed UI is not effective or well-tolerated, another drug 
with the lowest acquisition cost should be offered (NICE, 2015a). Second line antimuscarinic 
drugs include fesoterodine, tropsium chloride and popiverine. 
Mirabegron is a ß₃-adrenoceptor agonist, which activates beta-3-adrenoceptors causing the 
bladder to relax, which helps it to fill and store urine. It has a lower place in therapy and 
relatively weak evidence due to limited comparative data with other anti-muscarinics and 
limited long- term efficacy data. NICE (2015a) recomends mirabegron as an option for 
treating people for whom antimuscarinic drugs are contra-indicated, clinically ineffective or 
they have experienced unacceptable side effects.  
Botulinum toxin 
First line invasive intervention for OAB in men and women is multiple injections of 
Botulinum toxin (type A) directly into the bladder detrusor muscle every 6-12 months (NICE, 
2015a and NICE 2015b). Botulinum toxin (type A) is a neurotoxin that inhibits the release of 
acetylcholine from the presynaptic cholinergic nerve ending, which decreases the muscle 
contractibility owing to localized chemical denervation (Nitti et al; EMBARK Study Group, 
2013 and Andersson  et al, 2009). Botulinum toxin type A has been shown to reduce urinary 
symptoms of OAB by 35-50% compared with placebo   (NICE, 2015a). One of the main side 
effects is that the toxin can paralyse the bladder, leading to large residual urine volumes. 
Around 20% of patients will need to perform self catheterisation, therefore all women who 
are offered bbotulinum toxin injections must be willing and able to undertake self-
catheterisation prior to the procedure (NICE, 2015a). 
Treatment Mixed urinary incontinence   
NICE (2015a and NICE 2015b) recommend that bladder and pelvic floor re-training should be 
offered to women and men with mixed UI for a minimum of 3 months, as first line 
treatment. If following a 3 month period symptoms have failed to resolve then drug therapy 
may be initiated. However, bladder re-training and the non-pharmacological methods 
should continue alongside any drug treatment. 
Treatment of Nocturnal Enuresis (Nocturia and Nocturnal polyuria) 
Desmopressin is a synthetic analogue of vasopressin or antidiuretic hormone, which inhibits 
diuresis, while avoiding vasopressive effects (NICE, 2015a and BMA and RPS, 2016). When 
given at night it reduces nocturnal urine production (nocturia). NICE (2015) recommend 
desmopressin, may be considered specifically to reduce bothersome symptoms of UI or OAB 
at night. However the prescribing of desmopressin should be avoided in patients over 
65 years with cardiovascular disease or hypertension (NICE, 2015a). Serum sodium should 
be measured 3 days after the first dose. If serum sodium is reduced to below the normal 
range, the desmopressin treatment should be stopped (BMA and RPS, 2016). An alternative 
is to use a  late afternoon loop diuretic for patients with nocturnal polyuria (NICE, 2015a).  
 
Management of Benign Prostate Hyperplasia 
For men an enlarged prostate can block the urethra causing urinary retention which leads to 
symptoms of frequency and urgency, nocturia and overflow incontinence (NICE, 2015b). 
Within the male bladder neck and prostate, smooth-muscle tension is mediated by alpha-1-
adrenergic receptors. Alpha-adrenergic receptor–blocking agents decrease the resistance 
along the bladder neck, prostate, and urethra by relaxing the smooth muscle and allowing 
passage of urine. NICE (2015b) recommend that male patients with moderate to severe 
lower urinary tract symptoms (LUTS) are offered an alpha blocker (e.g. alfuzosin, doxazosin, 
tamsulosin or terazosin). A combination of an alpha blocker and a 5-alpha reductase 
inhibitor should be offered to men with bothersome moderate to severe LUTS and prostates 
estimated to be larger than 30 g or a PSA level greater than 1.4 ng/ml. Where symptoms are 
still present an anticholinergic should be considered in combination with an alpha blocker to 
men who still have storage symptoms.  
Conclusion 
The causes of urinary incontinence are varied and can be mutifactorial. Urinay incontinence 
is an under-reported problem that increases with age, and at all ages is more common in 
women than men. Healthcare professionals should be pro-active in asking patients about 
symptoms of urinary incontinence. Patients with urinary incontinence should undergo a 
comprehensive and holistic assessment of their symptoms and the effect on their quality of 
life a physical examination and urinalysis. Sucessful treatment must be tailored to the 
specific type of dysfunction and incontinence symptoms experienced by an individual.  
Reflective questions 
From reading this article:  
1. In the area where you work – which patuents are most likely to have or be at risk of 
urinary inconitnnece? 
2. What implications does this article/information have for your future practice? 
3. What other facts or issues do you feel are/were relevant to the information 
presented? 
4. What are some ways you could share this learning/information with your 
colleagues? 
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